- Another Paragon offshoot chooses reverse merger, this time for migraine drugsThey say stick to what you know. And Paragon Therapeutics knows how to do reverse mergers. The hub-and-spoke biologics company is moving its migraine drug offshoot, Mentari Therapeutics, onto the…Endpoints · 2mo ago↗ source
- Acceleron leaders and Westlake jumpstart new IPF biotechAfter success with the drug Winrevair, a band of entrepreneurs has found their next challenge in a difficult-to-treat lung disease. On Tuesday, Oorja Bio launched with a $30 million Series A roun…Endpoints · 2mo ago↗ source
- The state of consumer healthOn Thursday, the Health Tech team led a series of conversations at the Financial Times’ US Pharma and Biotech Summit, held in collaboration with Endpoints News. The sessions focused on ...